ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Pharmaceutical
Swiss pharma giant Roche has released results from a pivotal trial comparing Alecensa with the standard of care in lung cancer, which show a marked improval in progression-free survival. 6 June 2017
Pharmaceutical
Tagrisso (osimertinib), the potential new standard-of-care for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows efficacy in patients with disease progression to central nervous system (CNS) metastases, according to new evidence reported at ASCO 2017. 6 June 2017
Biotechnology
As the annual meeting of the American Society of Clinical Oncology enters its final day, US biotech major Celgene has released data on two of its co-development programs exploring T cell therapies. 6 June 2017
Biotechnology
Hutchison China MediTech has announced results from its pivotal Phase III trial of fruquintinib, its novel vascular endothelial growth factor receptor (VEGFR) kinase inhibitor in an oral presentation at ASCO 2017. 6 June 2017
Pharmaceutical
Taking three-month breaks during long-term treatment with letrozole did not reduce the risk of recurrence of breast cancer compared with taking the aromatase inhibitor continuously for five years among postmenopausal women with hormone-sensitive early breast cancer who had already completed four to six years of therapy. 5 June 2017
Biotechnology
Swiss pharma giant Roche presented data showing that fewer patients with HER2-positive breast cancer see their disease return after adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and chemotherapy at ASCO 2017 on Monday. 5 June 2017
Biotechnology
America’s Merck & Co will today present an additional five months of follow-up data on Keytruda in combination with pemetrexed and carboplatin (pem/carbo), in the first-line setting. 5 June 2017
Pharmaceutical
Privately-held German pharma Boehringer Ingelheim has presented encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma (MPM) at ASCO 2017. 5 June 2017
Pharmaceutical
At the annual meeting of the American Society of Clinical Oncology, Japanese pharma major Eisai has released data from a Phase III study into Lenvima as a first-line liver cancer therapy. 5 June 2017
Biotechnology
US biotech Amgen on Sunday announced new data from the Xgeva (denosumab) Phase III ‘482 study, the largest international multiple myeloma trial ever conducted. 4 June 2017
Pharmaceutical
In what could be one of the most significant advances announced at the 2017 ASCO Annual Meeting, AstraZeneca has presented the first positive Phase III data on a PARP inhibitor beyond ovarian cancer. 4 June 2017
Pharmaceutical
US pharma major Eli Lilly has added to its body of data on abemaciclib in breast cancer as it seeks to gain ground on rivals in the cyclin-dependent kinase (CDK) 4 and 6 inhibitor space. 4 June 2017
Biotechnology
US biotech Loxo Oncology revealed at the American Society of Clinical Oncology (ASCO) meeting in Chicago that it will be seeking US Food and Drug Approval for its for larotrectinib as a treatment for patients with TRK fusion-positive tumors along with presenting new data showing that three-quarters of participants in a combined analysis responded to the drug. 4 June 2017
Biotechnology
Eagerly-anticipated data from an ongoing Phase I/II trial into epacadostat in combination with Keytruda have been released, as the annual meeting of the American Society of Clinical Oncology continues in Chicago. 4 June 2017
Biotechnology
Bristol-Myers Squibb has announced data from a Phase II trial evaluating Opdivo as a monotherapy and in combination with Yervoy, in colorectal cancer (CRC). 4 June 2017
Biotechnology
Top-line data from Janssen’s eagerly-awaited clinical trial into Zytiga in combination with the standard of care for advanced prostate cancer have been released. 4 June 2017
Biotechnology
Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. 2 June 2017
Pharmaceutical
In our latest ASCO-themed expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, discusses why the oncology sector is seeing increased M&A activity and offers advice to buyers and sellers on how to maximize opportunities in the market and complete deals on the most favorable terms. 2 June 2017
Pharmaceutical
Phase III data on Anglo-Swedish pharma major AstraZeneca’s of Lynparza (olaparib) 300mg twice-daily tablet maintenance treatment shows that quality of life (QoL) is sustained alongside improved progression-free survival (PFS) in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer. 2 June 2017
Biosimilars
With data on so many innovative but expensive new oncology treatments being presented at ASCO 2017, it is a crucial period for biosimilars of three of the world's biggest-selling cancer drugs to deliver their promised savings, and this feature looks at the progress of these copycat biologics in reaching markets and patients. 1 June 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze